Stonehaven Incubate has partnered with human health player Regenosine to launch Vetosine, a new company that will develop and commercialize a first-in-class disease modifying osteoarthritis drug (DMOAD) for animals, with an initial focus on dogs. “Vetosine’s proprietary adenosine-based treatment will be a real game changer for the industry,” said Charlie Dawson, Venture Partner at Stonehaven…
Stonehaven Incubate has closed a further capital raising having secured significant investment from existing shareholder Elanco, and from Argenta, a leading animal health CRO and CMO. The funding will allow Stonehaven Incubate to expand investments into new portfolio companies and provide capital to potentially further invest in its existing five start-up businesses. Jarne Elleholm, CEO…
Andermatt, Switzerland (1 March 2021) – Stonehaven Incubate AG has appointed former Copenhagen Life Science Advisors Managing Partner, Jarne Elleholm as its new full time CEO with effect from 1 March. He replaces founding Stonehaven Incubate CEO and animal health executive, Dr Mark Heffernan, who will remain on the board of directors. The dedicated animal…
London/England, 7 December 2020 – Anifera, a new animal health company which aims to be the innovator and leader in researching and developing solutions for adjunct therapy with antibiotics, has announced an experienced line-up for its board. The board comprises Tony Benitz, Mark Heffernan, Malcolm Thomas and Simon Wheeler, each of whom has worked extensively…
London/England (2 November 2020) – Stonehaven Incubate AG and Agile Sciences Inc have completed initial studies validating the safety and efficacy of Agile’s small molecules, leading to the formation of a new company, Anifera Limited. Anifera will have the exclusive rights to manufacture, develop and commercialise the family of molecules in all applications in animal…
Stonehaven Incubate has teamed up with Sports Performance Tracking (SPT) and veterinary pain specialist, Dr. B Duncan X Lascelles – all leaders in their respective fields – to create a new venture that will commercialise sensor technology to improve animal health. AniV8 (pronounced An-i-vate) is designed to become the leading developer of clinical sensor technology…
Charlie Dawson has been appointed as Venture Partner at Stonehaven Incubate, adding to the established team, to identify new opportunities for animal health spin-outs and support partners with opportunity evaluation and growth. He has over 20 years of experience in strategy, marketing and leadership in the life sciences sector. Prior to joining Stonehaven Incubate, he…
26 August, Kansas: Stonehaven Incubate, a business incubator that brings disruptive human health technologies to the animal sector, has received capital backing from the global animal health company Elanco Animal Health Incorporated (“Elanco”). The capital will enable Stonehaven Incubate to advance new and existing opportunities, and expand its global team. Elanco’s investment accompanies additional participation…
Stonehaven Incubate has appointed Dr Gwynneth Thomas as Investment Manager based in London. Dr Thomas has extensive scientific and commercial experience in the areas of pathology, genomics, digital health, medical device and diagnostics. Dr Mark Heffernan, CEO of Stonehaven Incubate, said: “Gwynneth has spent her career at the intersection of business and science, gaining significant…
Stonehaven Incubate and Nuritas have announced a new collaboration which will see them join forces as part of a newly created joint venture. This world leading partnership will use cutting-edge AI technology to discover and develop advanced animal health solutions, with an initial focus on exploring feed ingredients. Stonehaven Incubate is a dedicated, animal health…
Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.
